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Streszczenie
Wstęp: Celem prezentowanej pracy była ocena wpływu
obniżenia masy ciała na stężenie w surowicy tlenku azotu
(NO, nitric oxide) i czynnika martwicy nowotworów a (TNF-a,
tumor necrosis factor a) oraz zbadanie czy istnieje związek
między aktywnością układu TNF a stężeniem w surowicy
NO po zmniejszeniu masy ciała.
Materiał i metody: Badaną grupę stanowiły 43 otyłe kobie-
ty (wiek 41,8 ± 11,9 lat, masa ciała 95,2 ± 15,0 kg, wskaźnik
masy ciała [BMI, body mass index] 36,5 ± 4,6 kg/m2). Badane
poddano 3-miesięcznej kompleksowej grupowej kuracji
odchudzającej. Zalecono im dietę 1000–1200 kcal i regularną
aktywność fizyczną. Nie stosowano leczenia farmakologicz-
nego. Przed i po kuracji oznaczono stężenie w surowicy me-
tabolitów tlenku azotu, TNF-a i jego rozpuszczalnych re-
ceptorów (sTNFR1, sTNFR2) za pomocą metody Enzyme-
-Linked ImmunoSorbent Assay (ELISA), insuliny przy użyciu
metody radioimmunologicznej (RIA, Radioimmunoassay),
a stężenie glukozy, cholesterolu, cholesterolu frakcji HDL
i triglicerydów — metodą enzymatyczną. Skład ciała oce-
niono za pomocą metody bioimpedancji przy użyciu apa-
ratu Bodystat.
Wyniki: Średni ubytek masy ciała wynosił 8,3 ± 4,3 kg. Po
obniżeniu masy ciała stężenie w surowicy TNF-a obniżyło
się istotnie (p < 0,000), a obu receptorów sTNFR1 i sTNFR2
istotnie się podwyższyło (p < 0,000). Nie obserwowano
natomiast zmian stężenia NO po zmniejszeniu masy ciała.
Przeprowadzono analizę regresji wieloczynnikowej ze
zmiennymi zależnymi, takimi jak DTNF-a, DsTNFR1,
DsTNFR2 i DNO. Zaobserwowano istotne korelacje między
DNO a wyjściowym stężeniem w surowicy TNF-a, sTNFR1
i sTNFR2.
Wnioski: Po obniżeniu masy ciała zaobserwowano zmniej-
szenie stężenia w surowicy TNF-a i wzrost stężenia obu re-
ceptorów TNF, nie stwierdziliśmy, natomiast zmian stężenia
w surowicy NO. Wydaje się, że zmiany aktywności układu
TNF mogą być mechanizmem kontrregulacyjnym, który
hamuje dalszą redukcję masy ciała. Związku między zmia-
nami aktywności układu TNF a stężeniem w surowicy NO
po redukcji masy ciała nie wykazano.
(Endokrynol Pol 2006; 5 (57): 487–493)
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Abstract
Introduction: The aims of the present study were to evalu-
ate the effect of weight-loss treatment on serum concentra-
tions of NO and TNF-a and to examine whether there is an
association between TNF-system activity and serum con-
centrations of NO after weight loss.
Material and methods: The study group involved 43 obese
women (aged 41.8 ± 11.9 years, weight 95.2 ± 15.0 kg, BMI
36.5 ± 4.6 kg/m2). The women were subjected to three-
month complex weight-loss treatment. Patients were advi-
sed to keep to a 1000–1200 kcal diet and to exercise regular-
ly. Pharmacological treatment was not administered. Serum
concentrations of nitric oxide metabolites, TNF-a and its
soluble receptors (sTNFR1, sTNFR2) were measured by
ELISA kits; insulin was measured by RIA and glucose, cho-
lesterol, HDL cholesterol and triglicerydes by an enzymatic
procedure before and after weight loss. Body composition
was determined by impedance analysis using Bodystat.
Results: The mean weight loss during treatment was 8.3 ±
± 4.3 kg. The serum concentrations of TNF-a decreased si-
gnificantly (p < 0.000) and both receptors sTNFR1 and
sTNFR2 increased significantly (p < 0.000) after weight loss.
No significant changes in serum concentrations of NO were
observed after weight loss. A multiple regression analysis
was performed using DTNF-a, DsTNFR1, DTNFR2 and
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DNO as dependent variables. A significant correlation was
observed between DNO and initial plasma concentrations
of TNF-a, sTNFR1 and sTNFR2.
Conclusions: This study demonstrates a decrease in serum
TNF-a concentration as well as an increase in plasma con-
centration of both TNF receptors but does not show any
change in serum concentrations of NO after weight-loss tre-
atment in obese women. It seems that changes in TNF-sys-
tem activity may be a counter-regulating mechanism, which
inhibits further body mass loss. We did not observe any as-
sociation between changes in TNF-system activity and se-
rum concentrations of NO after weight loss.
(Pol J Endocrinol 2006; 5 (57): 487–493)
Key words: nitric oxide, TNF-a, soluble TNF receptors, weight
loss
Introduction
Obesity is a chronic and widespread disease. Neverthe-
less, the mechanism of its pathogenesis and regulation
of weight reduction in the process of weight-loss treat-
ment is still unknown. It has been shown that weight
loss becomes proportionally smaller in consecutive
weeks of treatment. The mechanism responsible for
organism defence against the loss of reserve material
has yet to be discovered. Recently some authors have
put particular emphasis on genetic predisposition to this
disease [1–3]. Similarly, the development of studies fo-
cusing on cellular transmission and cytokines appears
promising in explanation of the pathomechanism re-
sponsible for weight gain and loss.
It has been shown in a number of studies that adi-
pose tissue alone generates many substances which may
participate in the regulation of its content in the orga-
nism [4, 5].
The results of recent in vivo and in vitro studies have
revealed that one of these substances is nitric oxide
(NO), which is shown to exert an inhibiting effect on
lipolysis stimulated by catecholamines [6, 7].
It is known that both iNOS (inducible nitric oxide
synthase) and eNOS (endothelial nitric oxide syntha-
se) participate in the production of NO in adipose tis-
sue; increased values of both of these substances were
found in isolated cells of adipose tissue in obese sub-
jects when compared to a lean control group [8]. Incre-
ased serum concentrations of NO in overweight and
obese subjects have also been shown in the recent stu-
dies conducted by Choi et al. [9] and by our results [10].
Tumor necrosis factor (TNF-a) is another substance
produced by the adipose tissue. There have been stu-
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dies suggesting that TNF-a participates in the develop-
ment of insulin resistance and may be responsible for
glucose and lipid metabolism disorders associated with
obesity and type 2 diabetes [11, 12].
Experimental studies performed on cultures of hu-
man adipose cells have shown that TNF-a may prevent
the development of adipose cells and that it impairs
their metabolic functions. One of the mechanisms which
inhibit lipogenesis probably arises from the strong in-
sulin-inhibiting activity in human adipocytes of TNF-a
and the decreased activity of lipoprotein lipase indu-
ced by TNF-a [13, 14]. Our previous studies have also
revealed increased serum concentrations of TNF-a in
obese subjects [15, 16].
The determination of circulating cytokines is compli-
cated by their relative instability in biological fluids and
the presence of soluble inhibitors may interfere with their
measurement. TNF is rapidly cleared from the circula-
tion and is frequently extremely low or undetectable. The
endogenous formation of TNF leads to the shedding of
sTNFRs (soluble receptors of tumour necrosis factor). The
increase in sTNFRs parallels or exceeds TNF-a produc-
tion and therefore measurement of their concentrations
may better reflect TNF-system activity [17].
There have been studies showing increased expression
of TNF receptors in adipose tissue and increased serum
concentrations of soluble TNF receptors in obesity [18].
A few studies have evaluated the effect of weight loss on
serum concentrations of TNF-a and its soluble receptors.
In these studies a decrease in serum concentrations of
TNF-a and an increase in serum concentrations of sTNFR1
and sTNFR2 after weight loss have been observed [16, 18].
However, there have been no studies concerning the in-
fluence of weight-loss treatment on changes in TNF-sys-
tem activity and serum concentrations of NO.
The aims of the present study, therefore, were to
evaluate the effect of weight-loss treatment on serum
concentrations of NO and TNF-a and to examine whether
there is an association between TNF-system activity and
serum concentrations of NO after weight loss.
Material and methods
The study was carried out in a group of 43 obese wo-
men aged 41.8 ± 11.9 years, weighing 95.2 ± 15.0 kg,
and with a BMI of 36.5 ± 4.6 kg/m2. Patient characteri-
stics and the effect of weight-loss treatment are presen-
ted in Table I.
All the individuals were diagnosed as having sim-
ple obesity without additional diseases, patients with
evidence of acute or chronic inflammatory diseases ha-
ving been excluded.
The women were subjected to a three-month com-
plex weight-loss treatment, during which they were
seen by a physician, a dietician, a psychologist and
a physical therapist every two weeks. Patients were ad-
vised to follow a 1000–1200 kcal diet, (with a limited
intake of simple carbohydrate and animal fats) and to
exercise regularly (30 minutes three times a week). Phar-
macological treatment was not administered.
The study was conducted after obtaining informed
consent from all the subjects. The study was approved
by the local Ethics Committee.
Before and after treatment weight and height were
measured and body mass index (BMI) was calculated
as the weight in kilograms divided by the square of the
height in metres. Body composition was determined by
impedance analysis using the Bodystat analyser.
In order to avoid the effect of diet on serum concen-
trations of metabolite NO, the subjects were given a list
of foods potentially rich in nitrates and were requested
to abstain from these for two days before sample collec-
tion. Specifically, herbal or black teas, beer, wine, cured
meat, fish and cheese were excluded from the diet.
The blood samples were collected after an over-
night fast before and after the weight-loss treatment.
Table I
Patient characteristics and the effect of weight-reducing treatment
Tabela I
 Charakterystyka pacjentów i efekty kuracji odchudzającej
Before After D
Weight [kg] 95.2±15.1 87.0±13.7*** –8.2±4.3
BMI [kg/m2] 36.5±4.6 33.4±4.6*** –3.1±1.7
Fat-free mass [kg] 53.0±7.5 50.8±6.0* –2.2±6.2
Fat-free mass (%) 56.0±8.3 58.9±5.8* 2.9±6.6
Body fat [kg] 41.5±12.1 35.4±9.0*** –6.1±6.4
Body fat (%) 43.4±7.9 40.7±5.7* –2.7±6.1
*p < 0.05; ***p < 0.0001
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Plasma glucose, cholesterol, HDL cholesterol and tri-
glicerydes were determined by an enzymatic procedu-
re using a commercially available test kit (Cormay). LDL
cholesterol was calculated using the Friedewald formu-
la. Insulin was determined by radioimmunoassay (DPC
Diagnostic Products Corporation, Los Angeles, USA).
The blood serum concentration of NO metabolites
was measured using the commercially available highly
sensitive ELISA kits (Genzyme Diagnostics, Cambrid-
ge, USA). The transient and volatile nature of NO ma-
kes it unsuitable for most convenient detection methods.
However, since most of the NO is oxidised to nitrite
(NO2
–) and nitrate (NO3
–), the concentration of these
anions was used as a quantitative measure of NO pro-
duction. After the conversion of NO3
– to NO2
–, the spec-
trophotometric measurement of NO2
– was accomplished
by using the Griess Reaction (1. NO + O2
– Æ ONO2– H
+
Æ NO3– + H+, 2. 2NO +O2 Æ N2O4 
H2OÆ NO2
– + NO3
– +
+ 2H+, 3. NO + NO2
– Æ N2O3 
H2O Æ 2NO2
– + 2H+). The
conversion of NO into nitrate and nitrite by these reac-
tions varies from system to system. The interaction of
NO in a system is measured by the determination of
total nitrate and nitrite concentrations in the sample.
R&D Systems’ Total Nitric Oxide Assay involves the
conversion of nitrate to nitrite by the enzyme nitrate
reductase. The detection of total nitrite is then determi-
ned as a coloured azo-dye product of the Griess Reac-
tion that absorbs visible light at 540 nm. The sensitivity
of the Total Nitric Oxide Assay is typically less than
1.35 mmol/L. The mean intra-assay coefficient of varian-
ce was 3.1%, ranging from 1.2 to 5.3%, and the mean
inter-assay coefficient of variance was 4.1%, in the ran-
ge 3.3–7.0%.
TNF-a and soluble forms of both TNF-a receptors
(sTNFR1, and sTNFR2) were measured using the com-
mercially available highly sensitive ELISA kits (Genzy-
me Diagnostics, Cambridge, USA). The minimum de-
tectable concentration of TNF-a is typically less than
0.18 pg/ml. The mean intra-assay coefficient of varian-
ce was 14.4%, ranging from 8.7 to 14.8%, and the mean
inter-assay coefficient of variance was 18.7%, range 16.1–
–22.6%. The minimum detectable concentration of
sTNFR1 is typically less than 3.0 pg/ml. The mean intra-
assay coefficient of variance was 2.9%, ranging from
2.7 to 6.9% and the mean inter-assay coefficient of va-
riance was 3.7%, range 5.8–8.8%. The minimum detec-
table concentration of sTNFR2 is typically less than
1.0 pg/ml. The mean intra-assay coefficient of variance
was 2.5%, ranging from 1.6 to 2.5% and the mean inter-
assay coefficient of variance was 3.5%, range 3.5–5.1%.
Data were analysed using the t-test and correlation
analysis was performed using Pearson’s and multiple
regression analyses. Values of p < 0.05 were conside-
red to be statistically significant.
Results
The mean weight loss during treatment was 8.3 ± 4.3 kg
and BMI decreased from 36.5 ± 4.6 at the baseline to
33.4 ± 4.6 after treatment. The effect of the weight-loss
treatment is presented in Table I.
Serum NO, TNF-a, sTNFR1 and sTNFR2
concentrations
No significant changes were observed in serum con-
centrations of NO after weight loss. Serum concentra-
tions of TNF-a decreased significantly after weight loss.
The most pronounced differences during weight loss
were observed in the soluble TNF receptors. Both re-
ceptors sTNFR1 and sTNFR2 increased significantly
(p < 0.0001) (Table II).
Serum insulin, glucose and lipid concentrations
Plasma concentrations of HDL cholesterol decreased
(p < 0.05) and plasma concentrations of glucose incre-
ased (p < 0.005); no significant changes were observed
in total cholesterol, LDL cholesterol, triglycerides and
insulin (Table III).
Table III
Serum concentrations of NO, TNF-a and TNF soluble receptors
Tabela III
Stężenie w surowicy NO, TNF-a i rozpuszczalnych receptorów TNF
Before After weight loss
NO [mmol/l ] 33.5±10.1 35.6±13.5
TNF-a [pg/ml] 6.9±2.4 5.4±1.6***
sTNF R1 [pg/ml] 1237.2±225.7 1432.8±304.9***
sTNF R2 [pg/ml] 1782.7±417.4 2063.0±340.6***
***p < 0.0001
Table II
Plasma lipids, glucose and insulin
Tabela II
Stężenie w surowicy lipidów, glukozy i insuliny
Before After weight loss
Total cholesterol [mg/dl] 207.2±33.7 206.3±33.8
HDL cholesterol [mg/dl] 53.9±10.6 51.1±8.1*
LDL cholesterol [mg/dl] 132.1±34.0 131.6±33.0
Triglycerides [mg/dl] 106.5±46.5 98.0±39.1
Glucose [mg/dl] 89.9±10.6 95.4±13.9**
Insulin [mIU/ml] 17.0±8.0 14.8±8.7
*p < 0.05; **p < 0.005
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Correlations between all study parameters
Significant positive linear correlations were found betwe-
en DNO and DBMI (r = 0.33; p = 0.03) and DTNF-a and
D of adipose tissue mass (kg) (r = 0.34; p = 0.03) and
DsTNFR1 and D of body mass (r = 0.32; p = 0.04).
There was also a significant negative correlation be-
tween DTNF-a and D glucose (r = –0.31; p = 0.04). No
correlation was observed between DNO and DTNF-a.
No correlation was found between serum NO con-
centrations and age, BMI, body mass, lipid levels and
serum TNF-a, sTNFR1 and sTNFR2 concentrations be-
fore and after treatment. No correlations were found
either between serum TNF-a and age, BMI, body mass,
lipid levels and serum TNF-a, sTNFR1 and sTNFR2 con-
centrations before and after treatment. We did not ob-
serve any association between serum concentrations of
NO and TNF-a, sTNFR1 and sTNFR2 and insulin.
A multiple regression analysis was performed using
DTNF-a , DsTNFR1, DsTNFR2 and DNO as dependent
variables. Models were fitted to estimate the role of age,
BMI, weight and body fat. Other models with DNO as
a dependent variable were fitted to estimate the role of
serum concentrations of insulin, TNF-a and soluble
TNF receptors.
DTNF-a was significantly associated with a reduc-
tion in adipose tissue mass (kg), DsTNFR1 with loss of
weight and DNO with a reduction in BMI (Table IV).
DNO was also significantly correlated with initial pla-
sma concentrations of TNF-a, sTNFR1 and sTNFR2.
Analysis of the remaining parameters revealed no si-
gnificant correlation.
Discussion
We observed a significant decrease in serum concen-
trations of TNF-a after weight-loss treatment. This re-
sult is in accordance with the findings of Kern et al. [19],
which show a decreased expression of TNF-a m RNA
and TNF-a protein levels in the adipose tissue of obese
humans after weight loss. A decrease in circulating TNF-a
after weight-loss treatment was also described by Brunn
et al. [20] and in our previous studies [15, 16]. On the
other hand, results contradictory to ours have also been
reported. Hauner et al. [18] showed no alteration in pla-
sma TNF-a concentrations in nine subjects after weight-
loss treatment over one year.
Moreover, decreased serum concentrations of TNF-a
correlate positively with decreased body fat mass, an
association which is confirmed by the findings of mul-
tiple regression analysis. This result is in accordance
with the study performed by Winkler et al. [21], which
revealed both the expression of the TNF-a protein in
fat deposits and the correlation of serum TNF-a with
adipocyte cell volume.
It is known that TNF-a participates in obesity-rela-
ted insulin resistance. Adipose tissue insulin resistance
could be explained as a mechanism for preventing fur-
ther adipocyte lipid accumulation. We observed no cor-
relation between serum concentrations of insulin and
TNF-a before and after treatment. Similar data concer-
ning serum TNF-a concentrations and insulin sensiti-
vity were obtained in our previous studies in which in-
sulin-sensitive and insulin-resistant obese subjects were
compared [22] and the effect of weight loss on these
parameters was assessed in insulin-sensitive and insu-
lin-resistant obese subjects [23].
Paradoxically, we observed a significant increase in
serum concentrations of glucose after weight loss and
negative associations between D glucose and DTNF-a.
This observation is difficult to account for and requires
further study.
It was shown that obese subjects express more TNFR2
mRNA in adipose tissue and more soluble TNFR2 in the
circulation than a lean control group. TNFR1 expression
and protein levels were similar in these subjects [24, 25].
However, in our recent study we found no differences
between serum concentrations of sTNFR1 and sTNFR2
in overweight, obese and lean women [10].
In the present study, as in the previous one [16],
serum concentrations of soluble TNF receptors signifi-
cantly increased after weight-loss treatment. We also
observed a significant positive correlation between an
Table IV
Regression analysis with DTNF-a, DsTNFR1 and DNO as dependent variables
Tabela IV
Analiza regresji z DTNF-a, DsTNFR1 i DNO jako zmiennymi zależnymi
Age (years) DBMI D Body fat [kg] D Body mass [kg]
DTNF-a –0.007 0.116*
DsTNFR1 –0.999 –19.415*
DNO –0.12 2.061*
*p < 0.05
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increased concentration of sTNFR1 and decreased body
mass, a correlation that was confirmed by multiple
regression analysis.
The question of whether the decrease in serum con-
centrations of TNF-a after the body-fat reducing treat-
ment is only a result of a decrease in its synthesis in
adipose tissue or whether it could also be caused by
increased serum concentrations of soluble TNF recep-
tors is a matter of interest and merits further study.
The result of increased TNF-a binding by its soluble
receptors besides the blocking of its binding by cell sur-
face receptors may stabilise and even enhance the ef-
fects of TNF-a by slowing down the dissociation rate
from a trimeric to an inactive monomeric structure. The
second property of soluble receptors is that they could
be serving as a reservoir of bio-active TNF, which pro-
longs the TNF-a activity [17].
In our previous study the value of serum concen-
trations of NO in obese women was significantly higher
when compared to controls [10]. In the present paper
no significant changes in serum concentrations of NO
were observed after weight-loss treatment. We also
observed a positive association between D serum con-
centration of NO and DBMI (r = 0.32; p = 0.03), which
was also demonstrated in multiple regression analysis
(Table IV).
However, the findings obtained by Choi et al. [9] show
a positive correlation between increased concentrations
of NO and BMI in both male and female adolescents. In
our [10] previous study we also observed a positive si-
gnificant correlation between serum concentrations of
NO and BMI. It therefore seems that the source of increa-
sed serum concentrations of NO after weight-loss treat-
ment may be tissues other than adipose tissue.
Because of a lack in the available literature both of
data concerning the activity level of NO synthases in
adipose tissue after weight-loss treatment and of stu-
dies assessing the influence of such treatment on se-
rum concentrations of NO, further investigation of this
question is required.
Conclusions
1. This study demonstrates a decrease in serum TNF-a
concentration as well as an increase in plasma con-
centration of both TNF receptors but does not show
a change in serum concentrations of NO after we-
ight-loss treatment in obese women. It appears that
changes in TNF-system activity may be a counter-
regulating mechanism which inhibits further loss of
body mass.
2. We observed no association between changes in
TNF-system activity and serum concentrations of
NO after weight loss.
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